PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2\ufe Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. by Guarneri, Valentina et al.
CLINICAL CANCER RESEARCH | CLINICAL TRIALS: TARGETED THERAPY
PIK3CA Mutation in the ShortHER Randomized Adjuvant
Trial for Patients with Early HER2þ Breast Cancer:
Association with Prognosis and Integration with PAM50
Subtype A  C
Valentina Guarneri1,2, Maria Vittoria Dieci1,2, Giancarlo Bisagni3, Alba A. Brandes4, Antonio Frassoldati5,
Luigi Cavanna6, Antonino Musolino7,8, Francesco Giotta9, Anita Rimanti10, Ornella Garrone11,
Elena Bertone12, Katia Cagossi13, Oriana Nanni14, Federico Piacentini15, Enrico Orvieto16, Gaia Griguolo1,2,




Purpose:We explored the prognostic effect of PIK3CAmutation
in HER2þ patients enrolled in the ShortHER trial.
Patients and Methods: The ShortHER trial randomized 1,253
patients with HER2þ breast cancer to 9 weeks or 1 year of adjuvant
trastuzumab combined with chemotherapy. PIK3CA hotspot muta-
tions in exon 9 and 20were analyzed by pyrosequencing. Expression
of 60 genes, including PAM50 genes was measured using the
nCounter platform.
Results: A mutation of the PIK3CA gene was detected in
21.7% of the 803 genotyped tumors. At a median follow-up of
7.7 years, 5-year disease-free survival (DFS) rates were 90.6%
for PIK3CA mutated and 86.2% for PIK3CA wild-type tumors
[HR, 0.84; 95% confidence interval (CI), 0.56–1.27; P ¼ 0.417].
PIK3CA mutation showed a favorable prognostic impact in
the PAM50 HER2-enriched subtype (n ¼ 232): 5-year DFS
91.8% versus 76.1% (log-rank P ¼ 0.049; HR, 0.46; 95% CI,
0.21–1.02). HER2-enriched/PIK3CA mutated versus wild-type
tumors showed numerically higher tumor-infiltrating lympho-
cytes (TIL) and significant upregulation of immune-related
genes (including CD8A, CD274, PDCD1, and MYBL2, a prolif-
eration gene involved in immune processes). High TILs as well
as the upregulation of PDCD1 and MYBL2 were associated with
a significant DFS improvement within the HER2-enriched sub-
type (HR, 0.82; 95% CI, 0.68–0.99; P ¼ 0.039 for 10% TILs
increment; HR, 0.81; 95% CI, 0.65–0.99; P ¼ 0.049 for PDCD1
expression; HR, 0.72; 95% CI, 0.53–0.99; P ¼ 0.042 for MYBL2
expression).
Conclusions: PIK3CAmutation showed no prognostic impact in
the ShortHER trial. Within the HER2-enriched molecular subtype,
patients with PIK3CA mutated tumors showed better DFS versus
PIK3CA wild-type, which may be partly explained by upregulation
of immune-related genes.
Introduction
HER2þ breast cancer is a heterogeneous entity with regards to gene
expression and gene mutation profile. Such heterogeneity may affect
both prognosis and treatment efficacy.
ThePI3Kpathway is frequently aberrantly activated in breast cancer
through activatingmutations in the helical (exon 9) or kinase (exon 20)
domain of the PIK3CA gene. The rate of tumors harboring a PIK3CA
gene mutation varies according to tumor subtype and has been
reported in the range of 20%–25% in early HER2þ breast cancer (1–3).
In vitro studies have shown that the activation of the PI3K pathway,
being downstream toHER2 andhubofmultiple intracellular signaling,
may drive escape from upstream inhibition of HER2 (4). In the
metastatic setting, patients with HER2þ and PIK3CA mutated breast
cancer treated with chemotherapy and anti-HER2 therapy experience
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poorer prognosis as compared with PIK3CA wild-type patients (5, 6).
In early breast cancer, a large pooled analysis of individual patients
data from prospective trials have demonstrated that PIK3CA muta-
tion is associated with reduced rate of pathologic complete response
after chemotherapy and anti-HER2 agents (3). However, investi-
gation of PIK3CA mutation in HER2þ patients enrolled in adjuvant
trials have not demonstrated any prognostic effect of this molecular
alteration, nor a predictive effect for trastuzumab added to adjuvant
chemotherapy (7–9).
However, because HER2þ disease is heterogeneous, one could
hypothesize that the effect of PIK3CA mutation may depend on the
tumor subtype. For example, in their pooled analysis of neoadjuvant
trials for HER2þ breast cancer, Loibl and colleagues showed that
PIK3CA mutation was associated with an improved long-term
outcome in hormone receptor–negative patients and to a worse
outcome in hormone receptor–positive patients (3). It is now
clear that the simple dichotomization of HER2þ breast cancer in
two subtypes according to hormone receptor status is oversimplis-
tic. PAM50 molecular intrinsic subtypes more accurately recapit-
ulate the complexity of HER2þ breast cancer biology (10). All
relevant intrinsic subtypes are represented within HER2þ disease,
with a distribution that varies according to hormone receptor
coexpression (10–12).
Currently, there are no data on the impact of PIK3CA mutation
within molecular intrinsic subtypes of HER2þ breast cancer.
In this study, we investigated the prognostic role of PIK3CA
mutation in HER2þ patients with breast cancer enrolled in the
prospective randomized ShortHER trial of adjuvant chemotherapy
and trastuzumab. Our aim was to evaluate the prognostic effect of




The ShortHER trial is a phase III multicentric trial of adjuvant
therapy that randomized (1:1) 1,253 patients with HER2þ early breast
cancer to:
Arm A (long): AC (adriamycin 60 mg/sqm plus cyclophosphamide
600 mg/sqm) or EC (epirubicin 90 mg/sqm plus cyclophosphamide
600 mg/sqm) every 3 weeks for four courses followed by paclitaxel
175 mg/sqm or docetaxel 100 mg/sqm every 3 weeks for four courses
combined with trastuzumab every 3 weeks for 1 year starting con-
comitant with taxane (8 mg/kg loading dose followed by 6 mg/kg
thereafter) or Arm B (short): docetaxel 100 mg/sqm every 3 weeks for
three courses with concomitant trastuzumab every week for 9 weeks
(4mg/kg loading dose followed by 2mg/kg thereafter) followed by FEC
(5-Fluorouracil 600 mg/sqm, epirubicin 60 mg/sqm, and cyclophos-
phamide 600 mg/sqm) every 3 weeks for four courses.
The aim was to demonstrate the noninferiority of short (Arm B)
versus long (Arm A) treatment in terms of disease-free survival
(DFS). Further details and results of the primary study endpoint are
reported elsewhere (13). Briefly, the study failed to demonstrate the
noninferiority of 9 weeks of the short treatment: 5-years DFS rates
were 88% in the long and 85% in the short arm [HR, 1.13; 90%
confidence interval (CI), 0.89–1.42, with a predefined noninferiority
margin of 1.29]. This analysis was approved by the competent
Ethical Committee in November 2014, patients provided signed
informed consent for tumor sample centralization and use for
research purpose. The study was conducted in accordance with
ethical guidelines (1964 Helsinki declaration and its later amend-
ments or comparable ethical standards).
The consort diagram for the analyses described in this work is
shown in Supplementary Fig. S1.
PIK3CA gene status
Formalin-fixed paraffin-embedded (FFPE) tumor blocks were
reviewed for quality and tumor content. Macro dissection from
5-mmol/L FFPE sections of primary tumor lesions containing
at least 20% of tumor cells were carried out to obtain tumor
DNA. DNA was extracted with the Maxwell 16 FFPE Tissue LEV
DNA Purification Kit (Promega) in the Maxwell 16 Instrument
(Promega), according to the manufacturer's instructions. PIK3CA
status was analyzed by pyrosequencing using anti-EGFR MoAb
response (PIK3CAstatus) Kit (Diatech Pharmacogenetics), accord-
ing to the manufacturer's instructions. Reactions were run on a
PyroMark Q96 ID (Qiagen). This kit allows identification of the
most important mutations in exon 9 (E542K, E545K, E545A,
E545G, Q546E, and Q546K) and exon 20 (M1043I, H1047Y,
H1047R, H1047L, G1049R, and G1049S) of the PIK3CA gene.
Tumor-infiltrating lymphocytes
Methods for tumor-infiltrating lymphocytes (TIL) assessment and
TILs data have been described previously (14). TILs data included in
this article derive from previous publication (14).
Gene expression
First, a section of centralized FFPE surgical tumor sample was
examined with hematoxylin and eosin staining to confirm diagnosis
and determine tumor surface area. If needed,microdissectionwas then
performed to avoid normal breast contamination. RNA was then
extracted from FFPE material using the High Pure FFPET RNA
IsolationKit (Roche) followingmanufacturer's protocol and quantified
using the NanoDrop spectrophotometer (Thermo Fisher Scientific).
A minimum of approximately 100 ng of total RNA was used to
measure the expression of 55 BC-related genes, including the
PAM50 genes, androgen receptor and some immune-related genes
(e.g., CD8A, CD4, PD1, and PD-L1), and five housekeeping
genes (ACTB, MRPL19, PSMC4, RPLP0, and SF3A1) using the
nCounter platform (Nanostring Technologies; ref. 15). Data were log
Translational Relevance
In early HER2þ breast cancer, PIK3CA mutation is associated
with reduced rate of pathologic complete response after neoadju-
vant chemotherapy and anti-HER2 agents without any impact on
disease-free or overall survival. This study evaluated the prognostic
role of PIK3CAmutation in the largest cohort from a randomized
trial of HER2þ patients treated with adjuvant chemotherapy and
trastuzumab. Beyond showing no prognostic effect in the whole
study cohort, our study provides unique data describing for the first
time a potential prognostic effect of PIK3CA mutation in the
HER2-enriched subtype. We also provide data supporting the
association of PIK3CA mutation and immune activation in the
HER2-enriched cohort, which might at least in part explain the
favorable prognostic effect. These data warrant further validation
and may contribute to the generation of an integrated multiple
biomarker score for HER2þ early breast cancer.
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base 2–transformed and normalized using the housekeeping genes.
The complete list of genes can be found in Supplementary Table S1.
Intrinsic molecular subtyping at baseline was determined using the
previously reported PAM50 subtype predictor (16).
Statistical analysis
Statistical analysis was carried out using IBMSPSSVersion 25 andR
project software 3.4.4 (17).
Association between variables was evaluated by the Pearson x2 test
or the Mann–Whitney test, according to the nature of the variables.
DFS was defined as the time between randomization and any of the
following events, whichever first: local, regional, and distant recur-
rence; contralateral breast cancer, excluding in situ carcinoma; other
second invasive primary cancer; death before recurrence or second
primary cancer. Patients without event were censored at the date of last
follow-up. The Kaplan–Meier method was used to estimate survival
curves, the log-rank test was used to compare between groups. Cox
proportional regression models were used to calculate HRs and 95%
CIs. The likelihood ratio test was used to evaluate the amount of
prognostic information provided by single variables when added to
integrated prognostic models within the HER2-enriched subtype.
Level of significance was P < 0.05.
To identify genes whose expression was significantly different
according to PIK3CAmutational status, we used a two-class unpaired
significance of microarrays (SAM) analysis with a FDR <10%.
No formal sample size calculation was performed, because the
sample population was based on the number of cases with centralized
tumor sample that was suitable for the present analysis.




Centralized tumor samples were available for 913 of the 1,253
randomized patients. A total of 803 cases (64% of all randomized
patients) had tumor samples suitable for PIK3CA assessment and were
included in this analysis (Supplementary Fig. S1). The characteristics
of the 803 patients analysed for PIK3CA and the comparison with the
450 patients from the ShortHER trial not included in this analysis are
shown in Supplementary Table S2. As compared with patients not
assessed for PIK3CA, those included in the PIK3CA cohort were older
[median age 56 (Q1–Q3: 48–64) vs. 54 (Q1–Q3: 46–62), P ¼ 0.012],
presentedmore often hormone receptor positive tumors (71% vs. 64%,
P¼ 0.010), and showed lower TILs levels [median 5 (Q1–Q3: 1–15) vs.
5 (Q1–Q3: 1–30), P ¼ 0.040].
PIK3CA
A mutation of the PIK3CA gene was detected in 21.7% of the
803 genotyped patients (n ¼ 174 mutated; n ¼ 629 wild-type).
Mutations in exon 9 and 20 occurred in 78 (9.7%) and 95 (11.8%)
cases, respectively (Supplementary Fig. S2 shows the pattern of
mutations).
Association between PIK3CA and clinicopathologic characteristics
is shown in Table 1. PIK3CA mutation occurred more frequently in
hormone receptor–positive versus hormone receptor–negative cases
(23.5% vs. 17.4%, P ¼ 0.057) and in postmenopausal vs. premeno-
pausal patients (23.8% vs. 17.7%,P¼ 0.050). No associationwith stage,
age, grade, TILs, and treatment arm was observed. Although the
distribution of PIK3CAmutation according to molecular subtype was
not significant, the rate of PIK3CAmutation was numerically higher in
Luminal A (22/86, 26%), followed by HER2-enriched (49/232, 21%),
Luminal B (8/42, 19%), and Basal-like (2/27, 7%).
PIK3CA and DFS
At a median follow-up of 7.7 years (95% CI, 7.5–7.9), 146 DFS
events occurred: 28 in patients with PIK3CA mutated tumor (28/174,
16%) and 118 in patients withPIK3CAwild-type tumor (118/629, 19%;
P¼ 0.419). Figure 1 shows the Kaplan–Meier DFS curves according to
PIK3CA gene status. DFS rates at 5 years were 90.6% for PIK3CA
mutated and 86.2% for PIK3CA wild-type groups (HR, 0.84; 95% CI,
0.56–1.27; P ¼ 0.417). Similar results were obtained in patients
randomized to receive 1 year of trastuzumab (HR, 0.86; 95% CI,
0.48–1.55) and in patients randomized to 9weeks of trastuzumab (HR,
0.84; 95% CI, 0.47–1.50).
We explored the prognostic effect of PIK3CA gene status accord-
ing to hormone receptor expression and intrinsic molecular sub-
type. Because of limited sample size and number of events within
individual intrinsic molecular sutbypes, we analyzed the impact of
PIK3CA mutations in two groups: HER2-enriched and non-HER2-
enriched (including Luminal A, Luminal B, Basal, and Normal-
like). Kaplan–Meier curves are shown in Fig. 2. PIK3CA mutation
had no significant effect on DFS in hormone receptor–positive
and hormone receptor–negative subgroups. According to intrinsic
subtype, patients with PIK3CA tumor experienced better DFS as
compared with PIK3CA wild-type in the HER2-enriched subgroup:
5-year DFS rate was 91.8% for PIK3CA mutated versus 76.1% for
PIK3CA wild-type groups, log-rank P ¼ 0.049 (HR, 0.46; 95% CI,
0.21–1.02; P ¼ 0.055). No difference in DFS was observed in non-
HER2-enriched patients according to PIK3CA gene status. The test
for interaction was not significant (P ¼ 0.269). Within the HER2-
enriched group, the positive prognostic impact of PIK3CAmutation
was particularly evident in patients with hormone receptor–
negative tumor (n tot ¼ 88; PIK3CA mutated n ¼ 14, 0 events;
PIK3CA wild-type n ¼ 74, 21 events): 5-year DFS rate was 100%
versus 75.6%, log-rank P ¼ 0.029. In HER2-enriched/hormone
receptor–positive patients (n tot ¼ 144, PIK3CA mutated n ¼
35, 7 events; PIK3CA wild-type n ¼ 109, 30 events), 5-year DFS
rate in the PIK3CA mutated and wild-type groups was 88.6% and
76.5%, respectively (log-rank P ¼ 0.329).
Clinicopathologic characteristics of PIK3CA mutated, HER2-
enriched tumors
To explore the potential reasons for favorable prognostic effect
of PIK3CA mutation within the HER2-enriched molecular subtype,
we first analyzed the association between PIK3CA gene status and
classic clinicopathologic factors in this patients’ subgroup (Supple-
mentary Table S3). PIK3CA genemutation was numerically associated
with hormone receptor–positive status (71% vs. 60%, P ¼ 0.128)
and higher TILs [median 8 (Q1–Q3:2–30) vs.median 5 (Q1–Q3:1–20),
P ¼ 0.164]. Figure 3 shows box plot for TILs levels according to
PIK3CA mutation in the entire HER2-enriched cohort as well as in
HER2-enriched/hormone receptor–positive andHER2-enriched/hor-
mone receptor–negative patients. In the HER2-enriched/hormone
receptor–negative subgroup, TILswere significantly higher in PIK3CA
mutated tumors [median 24% (Q1–Q3:10–50) for PIK3CA mutated
vs. median 7 (Q1–Q3:2–20) in PIK3CAwild-type, P¼ 0.005].We have
previously demonstrated the independent prognostic role of TILs in
the ShortHER trial (14). TILsmaintained a significant association with
DFS in the subgroup of HER2-enriched patients analyzed for PIK3CA
in this study: (HR, 0.82; 95% CI, 0.68–0.99; P ¼ 0.039 for each 10%
TILs increment].
PIK3CA in the ShortHER Trial
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Characteristics N (%) N (%) N (%) P
Total 174 (22%) 629 (78%) 803 (100%) —
Age (years)
<60 104 (60) 393 (62) 497 (62)
≥60 70 (40) 236 (38) 306 (38) 0.515
Median (Q1–Q3) 57 (50–64) 56 (48–64) 56 (48–64) 0.169
Menopausal status
Premenopausal 49 (28) 227 (36) 276 (34)
Postmenopausal 125 (72) 401 (64) 526 (66) 0.050
AJCC Stage
I 70 (40) 259 (41) 329 (41)
II 77 (44) 277 (44) 354 (44)
III 27 (16) 91 (15) 118 (15) 0.936
N stage
N0 85 (49) 343 (55) 428 (53)
N1-N2 61 (35) 191 (30) 252 (31)
N3 28 (16) 95 (15) 123 (15) 0.393
Hormone receptors
Negative 41 (24) 195 (31) 236 (29)
Positive 133 (76) 434 (69) 567 (71) 0.057
Histologic grade
Grade 1–2 54 (31) 172 (28) 226 (28)
Grade 3 118 (69) 448 (72) 566 (72) 0.348
TILs Median (Q1–Q3) 5 (1–15) 5 (1–15) 5 (1–15) 0.637
PAM50 Intrinsic subtype
LumA 22 (24) 64 (19) 86 (20)
LumB 8 (9) 34 (10) 42 (10)
HER2-enriched 49 (53) 183 (54) 232 (54)
Basal-like 2 (2) 25 (7) 27 (6)
Normal-like 11 (12) 35 (10) 46 (11) 0.358
Treatment arm
A long 93 (53) 312 (50) 405 (50)
B short 81 (47) 317 (50) 398 (50) 0.369
Abbreviations: AJCC, American Joint Committee on Cancer; LumA, luminal A; LumB, luminal B; TILs, tumor-infiltrating lymphocytes.
Figure 1.
Kaplan–Meier curves for DFS according to PIK3CA gene
mutation (n ¼ 803 patients from the ShortHER trial).
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Gene expression profile of PIK3CA mutated, HER2-enriched
tumors
We analyzed differences in gene expression among HER2-enriched
tumors according to PIK3CA gene status (Fig. 4). As reported
in Supplementary Table S4, the following genes were overexpressed
in PIK3CA mutated tumors (two-class unpaired SAM analysis,
FDR < 0.10): genes tracking luminal properties (ESR1 and PGR),
genes tracking proliferation and cell-cycle processes (MYC, MKI67,
CEP55, MYBL2), immune-related genes (CD8A, CD274 encoding
for PD-L1, PDCD1 encoding for PD-1), and a gene encoding for the
microtubule-associated protein tau (MAPT). Genes that resulted
downregulated in PIK3CA mutated tumors were: ERBB2, GRB7
(which is one of the 105 protein-encoding genes located in the same
amplicon as ERBB2) and TMEM45B [encoding for a member of the
transmembrane (TMEM) family, which includes proteins that span
biological membranes]. The same analysis was conducted stratified
by hormone receptor status (Supplementary Table S4): the only
differentially expressed genes were ERBB2 and GRB7 that resulted
downregulated in PIK3CA mutated tumors in the HER2-enriched/
hormone receptor–positive subgroup.
We then explored the association between differentially expressed
genes in PIK3CAmutated versus PIK3CA wild-type tumors and DFS,
in the cohort of HER2-enriched patients. Univariate cox regression
analysis is shown in Table 2. Two genes found to be upregulated in
HER2-enriched/PIK3CA mutated had a significant association with
improved DFS:MYBL2 (HR, 0.72; 95% CI, 0.53–0.00; P ¼ 0.042) and
PDCD1 (HR, 0.81; 95% CI, 0.65–0.99; P ¼ 0.049). Interestingly, as
further described in the Discussion, MYBL2 may be implicated in
processes linked to tumor immune activation. Among the genes
found to be downregulated in HER2-enriched/PIK3CA mutated
tumors, TMEM45B was associated with a worse DFS (HR, 1.31;
95% CI, 1.02–1.69; P ¼ 0.037).
Integrated prognostic models within the HER2-enriched
subtype
We assessed the amount of prognostic information provided
by PIK3CA mutation, TILs, PDCD1 expression, and MYBL2
expression when added to integrated prognostic models for the
HER2-enriched subtype. Among classic clinicopathologic factors,
stage was significantly associated with DFS (stage II vs. stage III:
Figure 2.
Kaplan–Meier curves for DFS according toPIK3CA genemutation in subgroups: hormone receptor–positive (A), hormone receptor–negative (B), HER2-enriched (C),
and non–HER2-enriched (D).
PIK3CA in the ShortHER Trial
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HR, 0.48; 95% CI, 0.26–0.88; P ¼ 0.019; stage I vs. stage III: HR,
0.37; 95% CI, 0.18–0.75; P ¼ 0.006). Age (HR, 1.02; 95% CI, 0.99–
1.04; P ¼ 0.264), histologic grade (grade 1–2 vs. 3: HR, 1.03; 95%
CI, 0.56–1.91; P ¼ 0.920), and hormone receptor status (positive vs.
negative: HR, 1.11; 95% CI, 0.65–1.90; P ¼ 0.703) were not associated
with DFS. When TILs, PIK3CA mutation, PDCD1 expression, or
MYBL2 expression were added as single variables to a model contain-
ing stage, all provided a significant amount of prognostic information
(Supplementary Table S5). The inclusion of either TILs or PDCD1
expression added significant prognostic information when included to
a model containing stage and PIK3CA status (Supplementary
Table S5). To the opposite, the inclusion of PIK3CA mutation to a
model containing stage and TILs, stage and PDCD1 expression,
or stage and MYBL2 expression was not significantly prognostic
(Supplementary Table S5).
Discussion
This study represents the largest cohort of patients with HER2þ
early breast cancer homogeneously treated with adjuvant chemother-
apy and trastuzumab in the context of a clinical trial that were
evaluated for PIK3CA mutation (n ¼ 803) and the first study to date
to investigate the prognostic role of PIK3CA mutation within molec-
ular intrinsic subtypes of HER2þ breast cancer (7–9).
We did not find any prognostic impact of PIK3CA genemutation in
the overall study cohort. This result is concordant with data from other
adjuvant trials showing no association between PIK3CAmutation and
long-term outcome (7–9). Moreover, in the NSABP B-31 and FinHER
studies, PIK3CAmutation was not predictive of reduced benefit from
adjuvant trastuzumab (7, 8). More recently, PIK3CAmutation did not
result associated with differential benefit from adjuvant neratinib in
the ExteNET trial (9). Two pooled analyses also confirmed no robust
impact of PIK3CA mutation on long-term outcome. Zardavas and
colleagues conducted a pooled analysis of more than 10,000 patients
with early breast cancer (18). In theHER2þ subgroup, they described a
numerically worse overall survival for patients with PIK3CAmutation
(HR, 1.17; 95% CI, 0.94–1.46). However, there was no impact of
PIK3CA mutation on invasive DFS (HR, 0.98) or distant DFS
(HR, 0.93). Moreover, not all the patients in this cohort received
adjuvant trastuzumab. In the pooled analysis of neoadjuvant trials in
HER2þ disease, although pathologic complete response rates after
chemotherapy and anti-HER2 treatment were lower in patients with
PIK3CA mutated tumor, this did not translate into a worse DFS (3).
Some hypotheses may explain this discrepancy in the effect of PIK3CA
mutation on pathologic complete response and long-term outcome.
First,PIK3CAmutationmight confer amore indolent biology thatmay
result in lower rates of pathologic complete response without affecting
long-term outcome, similarly to what is observed in case of HER2þ/
hormone receptor–positive breast cancer (19). In our cohort, patients
with PIK3CA mutation were more frequently postmenopausal and
showed more frequently HR-positive disease. However, the associa-
tion with hormone receptor status is not consistent across stud-
ies (3, 8, 9). According to intrinsic subtype, in our study, Luminal
A tumors showed the highest frequency ofPIK3CAmutation, although
the distribution of PIK3CAmutation across intrinsic subtypes was not
statistically significant. In the CALGB 40601 neoadjuvant study, the
highest rate of PIK3CA mutation was detected in Luminal B/HER2þ
tumors (20). A second potential explanation for discrepant data may
be linked to the observation that PIK3CA mutation not necessarily
determines downstream PI3K pathway activation (21), a factor that
may act as a confounder in studies looking at PIK3CA mutation.
Finally, one could also hypothesize a different role of PIK3CA muta-
tion in macroscopic versus microscopic disease. It has been previously
suggested that antibody-dependent cell-mediated cytotoxicity
Figure 3.
Box plot showing TILs levels according to PIK3CA mutation in HER2-enriched
patients: all patients (A), hormone receptor–positive (B), and hormone
receptor–negative (C).
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(ADCC), which is known as the main mechanisms of action of
trastuzumab, may be more effective, in the presence of PIK3CA
mutation, in case of microscopic disease, whereas in case of macro-
scopic disease it may be more difficult for ADCC to overcome
resistance due to downstream pathway activation (22, 23).
However, another hypothetic explanation may be that the role of
PIK3CA mutation depends on tumor subtype. A first hint was
suggested by the pooled analysis by Loibl and colleagues. In this study,
there was a significant interaction between PIK3CA mutation and
hormone receptor status for both pathologic complete response and
DFS: the reduction in pathologic complete response rate was signif-
icant in hormone receptor–positive disease and not in hormone
receptor–negative disease (Pinteraction¼ 0.036), PIK3CAwas associated
with significantly worse DFS in hormone receptor–positive patients
and with a trend for a better DFS in hormone receptor–negative
patients (Pinteraction ¼ 0.021; ref. 3).
In our study, we did not observe any difference in the impact of
PIK3CAmutation on outcome according to hormone receptor status.
However, we found an association between the presence of PIK3CA
mutation and improved outcome in HER2-enriched patients (5-year
DFS rate 91.8% vs. 76.1%, log-rank P¼ 0.049; HR, 0.46; 95% CI, 0.21–
1.02; P ¼ 0.055; test for interaction between molecular subtype and
PIK3CAmutation not significant). In this subgroup,PIK3CAmutation
was significantly prognostic beyond stage. On the basis of this result,
we investigated potential biological differences between PIK3CA
mutated and wild-type tumors within the HER2-enriched subtype.
We observed that HER2-enriched/PIK3CA mutated tumors were
numerically more frequently hormone receptor–positive, showed
increased expression of ESR1 and PGR and a decreased expression
of ERBB2 as compared with HER2-enriched/PIK3CA wild-type
tumors. These results suggest that PIK3CA mutation may be associ-
ated, even within theHER2-enriched subgroup, to amore luminal-like
and less HER2-addicted gene expression profile as compared with
PIK3CA wild-type tumors that might account for a more indolent
behavior. We also found that HER2-enriched/PIK3CA-mutated
tumors showed numerically higher TILs levels (statistically significant
in hormone receptor–negative patients), and upregulation in genes
involved in proliferation and immune response. In particular, when
exploring, within the HER2-enriched subtype, the association with
DFS of the features and genes found to be differentially expressed
between PIK3CA mutated and PIK3CA wild-type tumors, the
Figure 4.
Unsupervised clustering of 55genes acrossHER2-enriched tumors from the ShortHER trial (N¼232). Hormone receptor status (positive - blue; negative - yellow) and
PIK3CA mutational status (mutated - black; gray – wild-type) of each sample is also presented.
Table 2. HER2-enriched patients: univariate DFS Cox regression
analysis of genes found to be differentially expressed according to
PIK3CA gene status.
All patients
Gene HR (95% CI) P
Upregulated in PIK3CA mut
ESR1 1.06 (0.95–1.19) 0.300
PGR 1.04 (0.96–0.93) 0.490
MYC 0.84 (0.64–1.09) 0.193
MKI67 0.75 (0.49–1.17) 0.203
CEP55 0.64 (0.39–1.04) 0.073
MYBL2 0.72 (0.53–0.99) 0.042
CD8A 0.84 (0.68–1.05) 0.118
CD274 0.80 (0.57–1.12) 0.197
PDCD1 0.81 (0.65–0.99) 0.049
MAPT 0.98 (0.88–1.19) 0.801
Downregulated in PIK3CA mut
ERBB2 0.98 (0.81–1.20) 0.873
GRB7 0.97 (0.80–1.18) 0.773
TMEM45B 1.31 (1.02–1.69) 0.037
Abbreviations: CI, confidence interval; HR, hazard ratio.
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biological processes that seemed to affect prognosis to a larger extent
were those attributable to immune pathways. Indeed, increase TILs
levels and increased expression of PDCD1 and MYBL2 were all
significantly associated to improved prognosis. In multivariable mod-
els, TILs and PDCD1 added significant prognostic information beyond
stage and PIK3CAmutation, whereas PIK3CAmutation did not add a
significant amount of prognostic information beyondmodels contain-
ing stage and TILs or stage and PDCD1 expression. This observation
corroborates the hypothesis that immune features associated with
PIK3CA mutation, rather than PIK3CA mutation itself, may be the
main biological driver of the observed prognostic effect on DFS of
PIK3CA in univariate analysis. TILs are known to be a strong prog-
nostic factor in HER2þ breast cancer and reflect a general state of
immune activation. The significant prognostic effect of TILs in patients
with earlyHER2þ breast cancer treatedwith adjuvant therapy has been
previously demonstrated by our group and others (14, 24). PDCD1
expression is dynamic and tends to increase to counterbalance an
antitumor immune activation; the prognostic role of PD-L1 gene
expression in HER2-enriched breast cancer has not been clearly
established thus far (25). MYBL2 is a transcription factor involved in
cell cycle; however, there is evidence that it may also be implicated in
immune activation or in immune response–promoting processes.
Indeed, MYBL2 may mediate increase mutational load by inducing
APOBEC expression (26), may promote XCL1 expression in breast
cancer which is associated with a type 1 dendritic cell signature and
improved survival (27) and may be implicated in chromosomal
instability (28). In our article,MYBL2 provided significant prognostic
information beyond stage but not to a model containing stage and
PIK3CA mutation.
Interestingly, otherworks have linkedPIK3CAmutation to immune
infiltration. A recent study by Sobral-Leite and colleagues focused on
hormone receptor–positive patients (also including HER2þ cases)
found that tumors with PIK3CA mutation tend to have more CD8
cells and tumors enriched for FOXP3-positive cells show downstream
activation of the PI3K pathway (29). More functional data are needed
to better understand the interactions between the PI3K pathway and
the immune microenvironment.
The strengths of our study are: the large prospective cohort of
patients from a randomized trial, the large number of samples suitable
formolecular analyses, and the study design.Our study has limitations,
including: the fact that these analyses were not prespecified in the
protocol and the lack of statistical power that precluded the possibility
to evaluate the association of PIK3CA with DFS within each single
molecular intrinsic subtype separately. Another limitation is the lack of
correction for multiple comparisons, due to the exploratory nature of
the study, raising the possibility that some of the findings might be due
to chance. Therefore, our results should not be regarded as conclusive
but rather as hypothesis generating. However, they add novel findings
to the knowledge in the field that deserve validation.
In conclusion, our study provides unique data exploring the role of
PIK3CA mutation in HER2þ breast cancer by integrating the classi-
fication intomolecular intrinsic subtype; we describe for the first time a
potential prognostic effect of PIK3CAmutation in the HER2-enriched
subtype; we provide data supporting the association of PIK3CA
mutation and immune activation in the HER2-enriched cohort, which
might at least in part explain the favorable prognostic effect. These data
warrant further validation and may contribute to the generation of an
integrated multiple biomarker score for HER2þ early breast cancer.
Indeed, beyond classic clinicopathologic factors, it is now clear that
intrinsic subtypes and immune features represent independent prog-
nostic factors that could be combined into a prognostic score for
patients’ stratification. How and if PIK3CA mutation should be
integrated in prognostic models for HER2-enriched tumors needs to
be further evaluated.
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